A versatile pretargeting approach for tumour-selective delivery and activation of TNF superfamily members
出版年份 2017 全文链接
标题
A versatile pretargeting approach for tumour-selective delivery and activation of TNF superfamily members
作者
关键词
-
出版物
Scientific Reports
Volume 7, Issue 1, Pages -
出版商
Springer Nature
发表日期
2017-10-10
DOI
10.1038/s41598-017-13530-w
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Intra-tumor heterogeneity from a cancer stem cell perspective
- (2017) Pramudita R. Prasetyanti et al. Molecular Cancer
- Versatile strategy for controlling the specificity and activity of engineered T cells
- (2016) Jennifer S. Y. Ma et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Programmed Death Ligand 1 (PD-L1)-targeted TRAIL combines PD-L1-mediated checkpoint inhibition with TRAIL-mediated apoptosis induction
- (2016) Djoke Hendriks et al. OncoImmunology
- Toxicity and management in CAR T-cell therapy
- (2016) Challice L Bonifant et al. Molecular Therapy-Oncolytics
- C-type lectin-like molecule-1 (CLL1)-targeted TRAIL augments the tumoricidal activity of granulocytes and potentiates therapeutic antibody-dependent cell-mediated cytotoxicity
- (2015) Valerie R Wiersma et al. mAbs
- Systemic Agonistic Anti-CD40 Treatment of Tumor-Bearing Mice Modulates Hepatic Myeloid-Suppressive Cells and Causes Immune-Mediated Liver Damage
- (2015) José Medina-Echeverz et al. Cancer Immunology Research
- 4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity
- (2015) Todd Bartkowiak et al. Frontiers in Oncology
- Anti-CD40-mediated cancer immunotherapy: an update of recent and ongoing clinical trials
- (2014) Sufia Butt Hassan et al. IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY
- Unleashing the clinical power of T cells: CD19/CD3 bi-specific T cell engager (BiTE(R)) antibody construct blinatumomab as a potential therapy
- (2014) Z. Zimmerman et al. INTERNATIONAL IMMUNOLOGY
- Targeted delivery of CD40L promotes restricted activation of antigen-presenting cells and induction of cancer cell death
- (2014) Kim L Brunekreeft et al. Molecular Cancer
- Phase IA/II, multicentre, open-label study of the CD40 antagonistic monoclonal antibody lucatumumab in adult patients with advanced non-Hodgkin or Hodgkin lymphoma
- (2013) Michelle Fanale et al. BRITISH JOURNAL OF HAEMATOLOGY
- Clinical targeting of the TNF and TNFR superfamilies
- (2013) Michael Croft et al. NATURE REVIEWS DRUG DISCOVERY
- Phase 2, multicenter, open-label study of tigatuzumab (CS-1008), a humanized monoclonal antibody targeting death receptor 5, in combination with gemcitabine in chemotherapy-naive patients with unresectable or metastatic pancreatic cancer
- (2013) Andres Forero-Torres et al. Cancer Medicine
- Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors
- (2013) Robert H. Vonderheide et al. OncoImmunology
- Redirecting Gene-Modified T Cells toward Various Cancer Types Using Tagged Antibodies
- (2012) K. Tamada et al. CLINICAL CANCER RESEARCH
- Cell Surface Delivery of TRAIL Strongly Augments the Tumoricidal Activity of T Cells
- (2011) M. de Bruyn et al. CLINICAL CANCER RESEARCH
- Local Activation of CD8 T Cells and Systemic Tumor Eradication without Toxicity via Slow Release and Local Delivery of Agonistic CD40 Antibody
- (2011) M. F. Fransen et al. CLINICAL CANCER RESEARCH
- Phase 1b Study of Dulanermin (recombinant human Apo2L/TRAIL) in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Patients With Advanced Non-Squamous Non–Small-Cell Lung Cancer
- (2010) Jean-Charles Soria et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Dose-Escalation Study of Recombinant Human Apo2L/TRAIL, a Dual Proapoptotic Receptor Agonist, in Patients With Advanced Cancer
- (2010) Roy S. Herbst et al. JOURNAL OF CLINICAL ONCOLOGY
- Melanoma-associated Chondroitin Sulfate Proteoglycan (MCSP)-targeted delivery of soluble TRAIL potently inhibits melanoma outgrowth in vitro and in vivo
- (2010) Marco de Bruyn et al. Molecular Cancer
- Trimer Stabilization, Oligomerization, and Antibody-Mediated Cell Surface Immobilization Improve the Activity of Soluble Trimers of CD27L, CD40L, 41BBL, and Glucocorticoid-Induced TNF Receptor Ligand
- (2009) A. Wyzgol et al. JOURNAL OF IMMUNOLOGY
- Superior Activity of Fusion Protein scFvRit:sFasL over Cotreatment with Rituximab and Fas Agonists
- (2008) E. Bremer et al. CANCER RESEARCH
- Targeted delivery of a designed sTRAIL mutant results in superior apoptotic activity towards EGFR-positive tumor cells
- (2008) Edwin Bremer et al. JOURNAL OF MOLECULAR MEDICINE-JMM
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now